Samsung Biologics, 86,457 Shares Net Sold by Individuals in Last 5 Days... Stock Price 693,000 KRW (+1.61%)

As of 2:30 PM on the 2nd, Samsung Biologics is trading at 693,000 KRW, up 1.61% from the previous day. The trading volume is 64,864 shares, which is about 26.55% of the previous day's volume. Samsung Biologics is known as the bio business holding company of the Samsung Group.

On October 28, analyst Han Byunghwa of Eugene Investment & Securities stated, "The government recently extended the inspection period for pressure vessels, which are core equipment for biopharmaceutical manufacturers, from 2 years to 4 years. Maintenance is performed during the inspection period, and approximately one quarter's sales per factory are affected. Due to regulatory relaxation, the company's maintenance schedule has been reduced by half, with Plant 1 in December this year, Plant 2 in 2022, and Plants 1 and 3 in 2024. Since there will be no factory maintenance in 2021, the visibility of performance has improved. The company's 2021 sales and operating profit are estimated to increase by 19% and 35%, respectively, compared to this year, reaching 1.3 trillion KRW and 362.3 billion KRW." He set the target price for Samsung Biologics at 830,000 KRW.

Over the past five days, individual investors have net sold 86,457 shares of Samsung Biologics, while foreigners and institutions have net bought 31,927 shares and 51,876 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.